An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy

Cancer Prevention Research

Volumn 3, Issue 11, 2010, Pages 1409-1416

  Xie, Jenny ^a   Guillemette, Shawna ^a   Peng, Min ^a   Gilbert, Candace ^a   Buermeyer, Andrew ^b   Cantor, Sharon B ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; FANCONI ANEMIA GROUP J PROTEIN; FANCONI ANEMIA PROTEIN; HELICASE; HISTIDINE; LEUCINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLNITROSOUREA; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DNA CROSS LINKING; DNA METHYLATION; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; IMMUNOPRECIPITATION; MUTATION; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION;

EID: 78649309352     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0118     Document Type: Article

References (25)

1. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006;27:682-92.
2. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993;90:6424-8. (Pubitemid 23207225)
3. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993;362:652-4.
4. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol 2003;57:579-608.
5. 6-methylguanine residues in E. coli DNA. Nature 1982;296:868-9.
6. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001;22:1931-7. (Pubitemid 34065386)
7. 6-methylguanine adducts. Mol Cell 2006;22:501-10.
8. Lin DP, Wang Y, Scherer SJ, et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 2004;64:517-22.
9. Avdievich E, Reiss C, Scherer SJ, et al. Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis. Proc Natl Acad Sci U S A 2008;105:4247-52.
10. Cantor SB, Bell DW, Ganesan S, et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001;105:149-60.
11. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.
12. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005;8:255-65.
13. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. J Nat Genet 2005;37:934-5.
14. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-3.
15. Peng M, Litman R, Xie J, Sharma S, Brosh RM, Jr., Cantor SB. The FANCJ/MutLα interaction is required for correction of the cross-link response in FA-J cells. EMBO J 2007;26:3238-49. (Pubitemid 47057494)
16. Nakatani Y, Ogryzko V. Immunoaffinity purification of mammalian protein complexes. Methods Enzymol 2003;370:430-44.
17. Cantor S, Drapkin R, Zhang F, et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A 2004;101:2357-62.
18. Hidaka M, Takagi Y, Takano TY, Sekiguchi M. PCNA-MutSα-mediated binding of MutLα to replicative DNA with mismatched bases to induce apoptosis in human cells. Nucleic Acids Res 2005;33:5703-12.
19. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7:335-46.
20. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99.
21. Trojan J, Zeuzem S, Randolph A, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology 2002;122:211-9. (Pubitemid 34049209)
22. Cravo M, Afonso AJ, Lage P, et al. Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing. Gut 2002;50:405-12.
23. Fidalgo P, Almeida MR, West S, et al. Detection of mutations in mismatch repair genes in Portuguese families with hereditary nonpolyposis colorectal cancer (HNPCC) by a multi-method approach. Eur J Hum Genet 2000;8:49-53.
24. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res 2007;67:4595-604.
25. Barnetson RA, Cartwright N, van Vliet A, et al. Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum Mutat 2008;29:367-74.